Ligands of Immunopharmacology

WH-4-025 is a Salt-inducible kinase (SIK) inhibitor (WO2016023014 A2).Form:Solid

WH-4-025 is a Salt-inducible kinase (SIK) inhibitor (WO2016023014 A2).Form:Solid

WH-4-025 is a Salt-inducible kinase (SIK) inhibitor (WO2016023014 A2).Form:Solid

WH-4-025 is a Salt-inducible kinase (SIK) inhibitor (WO2016023014 A2).Form:Solid

WH-4-025 is a Salt-inducible kinase (SIK) inhibitor (WO2016023014 A2).Form:Solid

WH-4-025 is a Salt-inducible kinase (SIK) inhibitor (WO2016023014 A2).

WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression.Appearance:SolidIC50&amp

WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression.Appearance:SolidIC50&amp

YKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor with an IC 50 of 2.12 nM/1.40 nM/2.86 nM for SIK1 , SIK2 and SIK3 , respectively.In VitroYKL 06-062 (0.0004-16 μM 3 hours) increases MITF mRNA expression in a dose-dependent

YKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor with an IC 50 of 2.12 nM/1.40 nM/2.86 nM for SIK1 , SIK2 and SIK3 , respectively.In VitroYKL 06-062 (0.0004-16 μM 3 hours) increases MITF mRNA expression in a dose-dependent

YKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor with an IC 50 of 2.12 nM/1.40 nM/2.86 nM for SIK1 , SIK2 and SIK3 , respectively.In VitroYKL 06-062 (0.0004-16 μM 3 hours) increases MITF mRNA expression in a dose-dependent

YKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor with an IC 50 of 2.12 nM/1.40 nM/2.86 nM for SIK1 , SIK2 and SIK3 , respectively.In VitroYKL 06-062 (0.0004-16 μM 3 hours) increases MITF mRNA expression in a dose-dependent